New drug may offer safer, faster fix for Post-Surgery heart flutter

NCT ID NCT04748991

Not yet recruiting Disease control Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a newer drug, Vernakalant, works better than the standard Amiodarone for treating atrial fibrillation (irregular heartbeat) that often occurs after heart surgery. About 50 adults who recently had heart surgery will receive one of the two drugs. The main goal is to see which drug restores normal heart rhythm faster and with fewer side effects, like drops in blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vernakalant (also known as BRINAVESS) and Amiodarone (also known as Cordarone, Nexterone, Pacerone)
What this could lead to: If Vernakalant works better, it could offer a faster, safer way to restore normal heart rhythm after heart surgery, reducing time in the ICU and need for blood pressure medications.
What could go wrong: This is a small early-phase trial with only 50 participants, so results may not apply to everyone. Vernakalant may not be more effective than the standard drug Amiodarone, and side effects are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION POST-CARDIAC SURGERY

More trials for these conditions

Other studies related to the condition(s) this trial covers.